EPISODE · Dec 1, 2023 · 43 MIN
Trial and Error, High-End Holding Up? 12/1/23
from Power Lunch · host CNBC
Pfizer’s effort to join the weight-loss drug craze just hit a major setback. Patients are quitting its trial after experiencing unpleasant side effects. We’ll bring you the details, and the stock reaction.Plus, our Retail Ecosystem series concludes with a look at luxury stocks. Is the high-end consumer still buying, or spending money elsewhere on things like experiences? We’ll ask an industry insider. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
Pfizer’s effort to join the weight-loss drug craze just hit a major setback. Patients are quitting its trial after experiencing unpleasant side effects. We’ll bring you the details, and the stock reaction. Plus, our Retail Ecosystem series concludes with a look at luxury stocks. Is the high-end consumer still buying, or spending money elsewhere on things like experiences? We’ll ask an industry insider.
NOW PLAYING
Trial and Error, High-End Holding Up? 12/1/23
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·73m
Apr 18, 2026 ·95m
Apr 15, 2026 ·55m
Apr 13, 2026 ·68m
Apr 11, 2026 ·59m
Apr 9, 2026 ·66m